Sage Journals: Discover world-class research

Abstract

Shugoshin-like protein 1 (SGO1) participated in the proper progression of mitosis. This fundamental role has indicated the importance of this gene in the pathogenesis of cancer as a disorder of mitotic cell division. A previous high throughput study of long non-coding RNAs (lncRNAs) expression in lung cancer has identified aberrant expression of SGO1-antisense 1 (SGO1-AS1) in these specimens. In the current study, we quantified expression of SGO1 and SGO1-AS1 in 39 breast cancer tissues and their paired adjacent non-cancerous tissues (ANCTs). Expression of SGO1-AS1 was considerably decreased in tumoral tissues compared with ANCTs (expression ratio $=$ 0.49, $P$ value $=$ 0.03). However, we could not identify significant difference in expression of SGO1 between these two sets of specimens (expression ratio $=$ 2.9, $P$ value $=$ 0.2). Transcript quantities of SGO1-AS1 were associated with age at disease onset ( $P=$ 0.01). Expression of either gene was associated with hormone receptors status or clinical features such as grade and stage. There was an inverse correlation between expressions of genes in both sets of samples. Finally, transcript amounts of SGO1-AS1 could distinguish these two sets of samples with accuracy of 63% ( $P$ value $=$ 0.03). Our results imply significance of SGO1-AS1 in breast cancer and necessitate conduction of mechanistic studies to find the molecular pathways in this regard.

Keywords

Shugoshin-like protein 1 SGO1 lncRNA SGO1-AS1 breast cancer

Get full access to this article

View all access options for this article.

References

Watanabe

, Shugoshin: Guardian spirit at the centromere, Current Opinion in Cell Biology 17 (2005), 590–595.

McGuinness

B.E.

Hirota

Kudo

N.R.

Peters

J.M.

and Nasmyth

, Shugoshin prevents dissociation of cohesin from centromeres during mitosis in vertebrate cells, PLoS Biology 3 (2005), e86.

Kitajima

T.S.

Hauf

Ohsugi

Yamamoto

and Watanabe

, Human Bub1 defines the persistent cohesion site along the mitotic chromosome by affecting Shugoshin localization, Current Biology: CB 15 (2005), 353–359.

Wang

L.H.

et al., SGO1 is a potential therapeutic target for hepatocellular carcinoma, Oncotarget 6 (2015), 2023–2033.

Cutts

R.J.

et al., The pancreatic expression database: 2011 update, Nucleic Acids Research 39 (2011), D1023–1028.

Andre

et al., Exonic expression profiling of breast cancer and benign lesions: A retrospective analysis, The Lancet Oncology 10 (2009), 381–390.

Yamada

H.Y.

et al., Haploinsufficiency of SGO1 results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis, Cell Cycle (Georgetown, Tex) 11 (2012), 479–488.

et al., Genome-wide analysis of long noncoding RNA expression profiles in Human Xuanwei Lung Cancer, Clinical Laboratory 61 (2015), 1515–1523.

Edge

S.B.

and Compton

C.C.

, The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM, Annals of Surgical Oncology 17 (2010), 1471–1474.

10.

Wang

Yang

and Dai

, AACR, 2008.

11.

Murakami-Tonami

et al., SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells, Sci Rep-Uk 6 (2016).

12.

Lee

Rivera-Rivera

Moreno

C.S.

and Saavedra

H.I.

, The E2F activators control multiple mitotic regulators and maintain genomic integrity through SGO1 and BubR1, Oncotarget 8 (2017), 77649–77672.

13.

Iwaizumi

et al., Human SGO1 downregulation leads to chromosomal instability in colorectal cancer, Gut 58 (2009), 249–260.

14.

Jiao

Z.X.

and Woodruff

T.K.

, Age-related increase in aneuploidy and alteration of gene expression in mouse first polar bodies, J Assist Reprod Gen 31 (2014), 731–737.

15.

Werner

and Sayer

J.A.

, Naturally occurring antisense RNA: Function and mechanisms of action, Curr Opin Nephrol Hy 18 (2009), 343–349.

Assessment of SGO1 and SGO1-AS1 contribution in breast cancer

Abstract

Keywords

Get full access to this article

References